Алнуктамаб

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

2296827-07-9

immunoglobulin G1-kappa/lambda with domain crossover, anti-[Homo sapiens TNFRSF17 (TNF receptor superfamily member 17, tumor necrosis factor receptor superfamily, member 17, B cell maturation antigen, BCMA, BCM, TNFRSF13A, CD269)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], monoclonal antibody, bispecific, trivalent;
gamma1-lambda heavy chain anti-TNFRSF17 and anti-CD3E (VH-CH1-V-lambda-CH1-h-CH2-CH3) (1-671) [VH anti-TNFRSF17 (Homo sapiens IGHV3-23*01 (94.9%) -(IGHD) –IGHJ5*01 (93.3%)) CDR-IMGT [8.8.9] (26-33.51-58.97-105) (1-116) -Homo sapiens IGHG1*01, G1m17 (CH1 K26>E (146), K119>E (212), K120 (213) (117-214), hinge 1-6 (215-220)) (117-220) -10-mer bis(tetraglycyl-seryl) linker (221-230) -V-LAMBDA anti-CD3E (Mus musculus IGLV1*01 (81.2%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (80.0%) -IGLJ3*02 (100%)) CDR-IMGT [9.3.9] (256-264.282-284.321-329) (231-339)) -2-mer diseryl linker (340-341) -Homo sapiens IGHG1*01 G1m17,1, G1v14 CH2 A1.3, A1.2, G1v32 CH3 W22 (CH1 K120 (438) (342-439), hinge 1-15 (440-454), CH2 L1.3>A (458), L1.2>A (459), P114>G (553) (455-564), CH3 S10>C (578), D12 (580), L14 (582), T22>W (590) (565-669), CHS (670-671)) (342-671)],
(219-216')-disulfide with kappa light chain anti-TNFRSF17 (1'-216') [V-KAPPA (Homo sapiens IGKV3-20*01 (90.6%) -IGKJ1*01 (91.7%)) CDR-IMGT [7.3.10] (27-33.51-53.90-99) (1'-109') -Homo sapiens IGKC*01 (98.1%) E12>R (125), Q13>K (126), Km3 A45.1 (155), V101 (193) (110’-216’)];
(444-232''')-disulfide with VH-C-kappa light chain anti-CD3E, (1'''-232''') [VH (Homo sapiens IGHV3-23*03 (87.0%) -(IGHD) -IGHJ6*01 (90.9%)) CDR-IMGT [8.10.16] (26-33.51-60.99-114) (1'''-125''') -Homo sapiens IGKC*01 (99.1%) T1.3>S (127), Km3 A45.1 (171), V101 (209) (126'''-232''')];
gamma1 heavy chain anti-TNFRSF17 (1''-446'') [VH (Homo sapiens IGHV3-23*01 (94.9%) -(IGHD) -IGHJ5*01 (93.3%)) CDR-IMGT [8.8.9] (26-33.51-58.97-105) (1''-116'') -Homo sapiens IGHG1*01 G1m17,1, G1v14 CH2 A1.3, A1.2, G1v33 CH3 S22, A24, V86 (CH1 K26>E (146), K119>E (212), K120 (213) (117''-214''), hinge 1-15 (215''-229''), CH2 L1.3>A (233), L1.2>A (234), P114>G (328) (230''-339''), CH3 Y5>C (348), D12 (355), L14 (357), T22>S (365), L24>A (367), Y86>V (406) (340''-444''), CHS (445''-446'')) (117''-446'')],
(219''-216'''')-disulfide with kappa light chain anti-TNFRSF17 (1''''-216'''') [V-KAPPA (Homo sapiens IGKV3-20*01 (90.6%) -IGKJ1*01 (91.7%)) CDR-IMGT [7.3.10] (27-33.51-53.90-99) (1''''-109'''') -Homo sapiens IGKC*01 (98.1%) E12>R (125), Q13>K (126), Km3 A45.1 (155), V101 (193) (110''''-216'''')];
dimer (450-225'':453-228'':578-348'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Поделиться этой страницей